Sign up USA
Proactive Investors - Run By Investors For Investors
Market: AIM
52-week High/Low: 116.00p / 61.50p
Sector: Pharma & Biotech
Market Cap: 43.08M
Phone: +44 (0)844 414 0452
Address: Unit 20, Ash Way, Thorp Arch Estate, Wetherby LS23 7FA.
Avacta Group Plc

Avacta Group Plc

Avacta’s principal focus is on its proprietary Affimer® platform, a novel engineered alternative to antibodies that has wide application in diagnostics, therapeutics and research.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer proteins, which can be quickly generated to bind with high specificity and affinity to a wide range of targets, have been designed to address these negative performance issues. 

Avacta has a pre-clinical drug development programme with a primary focus on immuno-oncology as well as partnered development programmes. Avacta is also commercialising non-therapeutic Affimer reagents through licensing to developers of research tools and diagnostics.

Avacta Group Plc

Interactive graph

col 3
col 4
col 5
col 6

Avacta Group Plc Snapshot

Our mission is to shape the future of medicine by providing powerful reagents for research and diagnostics, and by developing safe and efficacious medicines.

At Avacta we have developed Affimer® technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.

Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.

"What really excites me, and drives the company, is the opportunity to change the way life scientists explore the complexity of the proteome and the myriad of interactions that define us as humans."


Reagents & Diagnostics

Affimer reagents are ideal tools for use in a wide variety of diagnostic and research applications. With a rapid development timeline Affimer reagents represent a quick solution to rapidly unfolding research needs and ever growing needs for quality diagnostic reagents with consistent supplies. Custom Affimer solutions are available to meet your Diagnostic and Research needs.

Affimer technology offers highly specific target recognition in a variety of complex samples, while retaining both chemical and thermal stability. Affimer molecules offer flexibility in formatting via both genetic and chemical means. A single strategic cysteine residue addition allows for site specific functionalisation with enzymes, dyes, fluors, or immobilization onto a variety of surfaces. In addition to classical chemical methods of modification, we are also able to express genetic modifications to optimise performance (GFP, carrier proteins, and even multimers).

We develop highly specific, reproducible, and stable tools for use in point of care (POC) tests, research assays and immunoassays, and bioprocessing and separations from complex matrices.

Please click here to view our therapeutic program

Please click here to see the benefits of Affimer therapeutics

Please click here to see applications of Affimer therapeutics

Affimer Technology

Affimer reagents and therapeutics are a class of non-antibody binding proteins that have been engineered for a wide range of applications where antibodies and aptamers have limitations. They can be used to detect difficult targets, can easily be formatted for a wide range of applications and can be easily and cost effectively manufactured.

What is an Affimer?

Two Affimer scaffolds, based on similar protein conformations, have been developed. The first is of human origin, based on the naturally occurring human protease inhibitor Stefin A, and is ideal for therapeutic applications. The second is based on a consensus sequence of Cystatin A from a number of plant species and is ideal for use in reagents and diagnostics.

For more information, please click here



Avacta Group Plc Timeline

Market Reports Including AVCT

Video RSS


Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use